Dual Antiplatelet Therapy (Aspirin + Clopidogrel)
Treatment for Ischemic Stroke
Typical Dosage: Aspirin 75-325mg loading, 75-100mg daily; Clopidogrel 300-600mg loading, 75mg daily
Effectiveness
80%
Safety Score
70%
Clinical Trials
29
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
Aspirin 75-325mg loading, 75-100mg daily; Clopidogrel 300-600mg loading, 75mg daily
Time to Effect
days to weeks
Treatment Duration
21-90 days
Evidence Quality
HIGHNumber Needed to Treat (NNT)
50(Treat 50 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
250(Treat 250 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$1,200
Side Effect Mgmt:$0
Total Annual:$1,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$5,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$400
Comparison vs Aspirin Monotherapy
Cost Difference
+$50/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Dual Antiplatelet Therapy (Aspirin + Clopidogrel) Outcomes
for Ischemic Stroke
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+25%
Common Side Effects
Major Bleeding (non-ICH)
+1%
Minor Bleeding
+8%
Dyspepsia
+7%
Active Clinical Trials
9 active trials recruiting for Dual Antiplatelet Therapy (Aspirin + Clopidogrel) in Ischemic Stroke
Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPrime)
NCT06638151RECRUITINGPHASE2
200 participants
INTERVENTIONAL
Edmonton, Canada
Started: Sep 2, 2025
Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke
NCT07095790RECRUITINGPHASE4
580 participants
INTERVENTIONAL
Suzhou, China +17 more
Started: Aug 30, 2025
Drug-eluting Stenting Versus Medical Treatment for Extracranial Vertebral Artery Stenosis
NCT05885932RECRUITINGNA
472 participants
INTERVENTIONAL
Beijing, China
Started: Aug 25, 2023
Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke
NCT05910125NOT YET RECRUITINGPHASE4
472 participants
INTERVENTIONAL
Guangzhou, China
Started: Jul 1, 2023
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
NCT06943586RECRUITINGNA
200 participants
INTERVENTIONAL
Birmingham, United States
Started: Apr 9, 2025
Pair Antiplatelet THerapy in Ischemic Stroke With Intracranial Artery Stenosis
NCT06243133NOT YET RECRUITINGPHASE4
1.1K participants
INTERVENTIONAL
Chengdu, China
Started: Jul 1, 2024
Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients with Acute Ischemic STROKE
NCT06853535NOT YET RECRUITINGPHASE3
5.14K participants
INTERVENTIONAL
Chengdu, China
Started: Apr 1, 2025
PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years
NCT05387954RECRUITINGPHASE3
792 participants
INTERVENTIONAL
Amiens, France +40 more
Started: Jul 7, 2023
Genotype Guided Antiplatelet Therapy in Ischemic Stroke
NCT05763862RECRUITINGNA
350 participants
INTERVENTIONAL
Singapore, Singapore
Started: Apr 24, 2023
Completed Clinical Trials
4 completed trials for Dual Antiplatelet Therapy (Aspirin + Clopidogrel) in Ischemic Stroke
A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA
NCT05476081COMPLETED
2.24K participants
OBSERVATIONAL
Avezzano, Italy +126 more
Started: Feb 3, 2021
Chronic Kidney Disease (CKD) Platelet Study
NCT03649711COMPLETEDPHASE3
76 participants
INTERVENTIONAL
Little Rock, United States +1 more
Started: Nov 1, 2018
Platelet Reactivity in Acute Non-disabling Cerebrovascular Events
NCT02506140COMPLETEDPHASE2, PHASE3
675 participants
INTERVENTIONAL
Fuzhou, China +24 more
Started: Aug 1, 2015
Intensive Drug Therapy for Ischemic Stroke Caused by Severe Intracranial Arterial Stenosis
NCT05996978COMPLETED
42 participants
OBSERVATIONAL
Shanghai, China
Started: Feb 1, 2020
Showing 20 of 30 total trials